Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28007740 | 0.98 | NOS1 (0.50) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 | |
| SCHEMBL3828155 | 0.98 | NOS1 (0.50) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 | |
| SCHEMBL11588307 | 0.98 | NOS1 (0.50) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 | |
| SCHEMBL9729165 | 0.98 | NOS1 (0.50) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 | |
| SCHEMBL14643881 | 0.98 | NOS1 (0.50) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 | |
| SCHEMBL2373929 | 0.94 | NOS1 (0.53) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 | |
| Acetamide SCHEMBL9942181 | 0.90 | GABRA5 (0.50) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 | |
| SCHEMBL5911714 | 0.86 | — | — | |
| Pyridine SCHEMBL27812107 | 0.83 | NOS1 (0.51) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 | |
| Pyridine SCHEMBL27812133 | 0.82 | NOS1 (0.50) | NOS1SMN1; SMN2GABRA5GABRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000838-A1 | MASITINIB FOR THE TREATMENT OF SICKLE CELL DISEASE | AB SCIENCE (FR) | 2023-01-05 | — | — | US | claimed |
| EP-3240538-B1 | USE OF MASITINIB FOR TREATMENT OF AN AMYOTROPHIC LATERAL SCLEROSIS PATIENT SUBPOPULATION | AB SCIENCE (FR) | 2021-09-29 | — | — | EP | claimed |
| EP-3831384-A1 | USE OF MASITINIB FOR THE TREATMENT OF EOSINOPHILIC ASTHMA | AB Science (FR) | 2021-06-09 | — | — | EP | claimed |
| US-20190117683-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2019-04-25 | — | — | US | claimed |
| US-10092564-B2 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | AB SCIENCE (FR) | 2018-10-09 | — | — | US | claimed |
| US-20180117037-A1 | USE OF MASITINIB FOR TREATMENT OF AN AMYOTROPHIC LATERAL SCLEROSIS PATIENT SUBPOPULATION | AB SCIENCE (FR) | 2018-05-03 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | claimed |
| EP-3240538-A1 | USE OF MASITINIB FOR TREATMENT OF AN AMYOTROPHIC LATERAL SCLEROSIS PATIENT SUBPOPULATION | AB Science (FR) | 2017-11-08 | — | — | EP | claimed |
| WO-2017162884-A1 | USE OF MASITINIB FOR TREATMENT OF AN AMYOTROPHIC LATERAL SCLEROSIS PATIENT SUBPOPULATION | AB SCIENCE (FR) | 2017-09-28 | — | — | WO | claimed |
| EP-1904065-A2 | USE OF DUAL C-KIT/FGFR3 INHIBITORS FOR TREATING MULTIPLE MYELOMA | AB Science (FR) | 2008-04-02 | — | — | EP | claimed |
| WO-2007026251-A2 | USE OF DUAL C-KIT/FGFR3 INHIBITORS FOR TREATING MULTIPLE MYELOMA | AB SCIENCE (FR) | 2007-03-08 | — | — | WO | claimed |
| US-20050239860-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-10-27 | — | — | US | claimed |
| EP-1195641-B1 | Film/Screen system and image-forming system for use in direct X-ray applications | AGFA GEVAERT (BE) | 2004-12-29 | — | — | EP | claimed |
| EP-1432687-A2 | SUBSTITUTED 5-MEMBERED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-06-30 | — | — | EP | claimed |
| WO-2003093242-A2 | SUBSTITUTED 5-MEMBERED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030162776-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| US-6528227-B2 | Radiation-sensitive black-and-white silver halide photographic material in contact with screen sheets designed to emit electrons when exposed to X-rays with an energy greater than or equal to 10 kVp; radiology | AGFA-GEVAERT (BE) | 2003-03-04 | — | — | US | claimed |
| US-20020076640-A1 | Film/screen system and image-forming system for use in direct X-ray applications | AGFA-GEVAERT (BE) | 2002-06-20 | — | — | US | claimed |
| EP-1195641-A1 | Film/Screen system and image-forming system for use in direct X-ray applications | Agfa-Gevaert (BE) | 2002-04-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162776-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, SERPINC1 | NOS1 2572/4885SMN1; SMN2 4292/4885GABRA5 2620/4885 |
| US-10092564-B2 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | MAST3, MAST1, KIT | NOS1 1504/4885SMN1; SMN2 11/4885GABRA5 2583/4885 |
| US-20230000838-A1 | MASITINIB FOR THE TREATMENT OF SICKLE CELL DISEASE | MPST, KSR2, HCLS1 | NOS1 1374/4885SMN1; SMN2 274/4885GABRA5 3598/4885 |
| US-20180117037-A1 | USE OF MASITINIB FOR TREATMENT OF AN AMYOTROPHIC LATERAL SCLEROSIS PATIENT SUBPOPULATION | MAST3, MAST1, KIT | NOS1 1504/4885SMN1; SMN2 11/4885GABRA5 2583/4885 |
| US-20050239860-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, SERPINC1 | NOS1 2572/4885SMN1; SMN2 4292/4885GABRA5 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.